Russia to sell 100 million doses of COVID-19 vaccine to India: Report
Clinical trials of the Russian vaccine in India are expected to follow and to be held jointly with a major listed pharmaceutical company, Reuters reported. Both the trials and supply deal depend on domestic regulatory approval.
Russia's sovereign wealth fund has agreed a deal to sell 100 million doses of its COVID-19 vaccine, Sputnik-V, to a major listed pharmaceutical company in India, Reuters reported citing a source close to the deal on Wednesday.
Clinical trials of the Russian vaccine in India are expected to follow and to be held jointly with this firm, the report said. Both the trials and supply deal depend on domestic regulatory approval.
The Russian Direct Investment Fund (RDIF) has already inked vaccine supply deals with Kazakhstan, Brazil and Mexico and has reached a manufacturing partnership agreement with India to produce 300 million doses of the Sputnik-V vaccine.
RDIF will announce the name of the Indian firm later on Wednesday, Reuters reported.
Russia has billed Sputnik V as the first vaccine against coronavirus to be registered in the world. Large-scale trials, known as Phase III, involving at least 40,000 people, were launched in Russia on August 26 but have yet to be completed. It is developed by Moscow's Gamaleya Institute.
Last month, India's Health Ministry had said that the country was in communication with Russia over Sputnik-V.
"As far as Sputnik-V vaccine is concerned, both India and Russia are in communication. Some initial information has been shared while some detailed information is awaited," Union Health Secretary Rajesh Bhushan had said at a press conference.
Russian President Vladimir Putin earlier said that his own daughter had received the vaccine.